OncoMatch/Clinical Trials/NCT06447597
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Is NCT06447597 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies B007 for generalized myasthenia gravis.
Treatment: B007 — The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CHRNA1 antibody positive
Serum AchR(Acetylcholine receptor)-Ab ... was positive during screening
Required: MUSK antibody positive
Serum ... MUSK-Ab was positive during screening
Disease stage
Excluded: Stage MGFA I, MGFA V
Subjects with MGFA I and V type [excluded]
Demographics
Prior therapy
Must have received: standard of care for generalized myasthenia gravis
subjects received at least one gMG stable dose of SoC, and maintain a stable dose throughout the test
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06447597 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard of care for generalized myasthenia gravis.
Does this trial require CHRNA1?
Yes, CHRNA1 antibody positive is a required biomarker for enrollment.
Does this trial require MUSK?
Yes, MUSK antibody positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify